Upload
marylou-townsend
View
217
Download
1
Tags:
Embed Size (px)
Citation preview
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Baseline demographic features and laboratory measurements by treatment allocation
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Average use of study simvastatin plus ezetimibe or non-study statin and average change in plasma LDL
cholesterol from baseline, by period of follow-up
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Life-table plot of effects of allocation to simvastatin plus ezetimibe versus placebo on major atherosclerotic events
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Major atherosclerotic events subdivided by type
C. Baigent, et al. Lancet 2011;Epub 9 June
Major atherosclerotic events by baseline
characteristics
χ² tests on 1 degree of freedom
are shown for heterogeneity
between rate ratios within
dichotomous categories and
for trend within other
categories. BP=blood pressure.
MDRD=Modifi ed Diet in
Renal Disease formula.17
GFR=glomerular fi ltration rate
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Cause-specific and overall mortality
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Cancer incidence and cancer mortality by site
C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June
Effects of allocation to simvastatin plus ezetimibe on muscle and hepatobiliary system
C. Baigent, et al. Lancet 2011;Epub 9 June
Effects of LDL-lowering therapy
on particular vascular outcomes in four trials in patients with chronic kidney disease and 23 trials
in other patients
Data from the Cholesterol Treatment Trialists’ Collaboration. χ² tests are shown for eterogeneity between rate ratios for each outcome in the four trials (4D, ALERT, AURORA, and SHARP) in patients with chronic kidney disease. MI=myocardial infarction. LDL-C=LDL-cholesterol.